Publications by authors named "Claes Malm"

Claim this Profile
G
Graft-versus-mastocytosis effect after donor lymphocyte infusion: Proof of principle.
Hans Hägglund, Akif Selim Yavuz, Arta Dreimane, Claes Malm, Anders Sundin

Eur J Haematol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
Martin Höglund, Fredrik Sandin, Karin Hellström, Mats Björeman, Magnus Björkholm, Claes Malm

Blood· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
Maciej Machaczka, Jan-Erik Johansson, Mats Remberger, Helene Hallböök, Claes Malm

Leuk Lymphoma· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT.
Arnon Nagler, Myriam Labopin, Avichai Shimoni, Ghulam J Mufti, Jan J Cornelissen, Claes Malm

Eur J Haematol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study.
Vladimir Lazarevic, Mats Remberger, Hans Hägglund, Gunnar Juliusson, Hamdy Omar, Claes Malm

Leuk Lymphoma· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Bengt Simonsson, Tobias Gedde-Dahl, Berit Markevärn, Kari Remes, Jesper Stentoft, Claes Malm

Blood· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: a retrospective study.
Vladimir Lj Lazarevic, Mats Remberger, Hans Hägglund, Helene Hallböök, Gunnar Juliusson, Claes Malm

Am J Hematol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
Magnus Björkholm, Asa R Derolf, Malin Hultcrantz, Sigurdur Y Kristinsson, Charlotta Ekstrand, Claes Malm

J Clin Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden.
Vladimir L J Lazarevic, Hans Hägglund, Mats Remberger, Anders Wahlin, Helene Hallböök, Claes Malm

Leuk Lymphoma· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.
Mats Merup, Vladimir Lazarevic, Hareth Nahi, Björn Andreasson, Claes Malm

Br J Haematol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
Ulla Olsson-Strömberg, Martin Höglund, Magnus Björkholm, Inger Braide, Karin Carlson, Claes Malm

Leuk Lymphoma· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.
Bengt Simonsson, Gunnar Oberg, Mats Bjoreman, Magnus Bjorkholm, Jan Carneskog, Claes Malm

Acta Haematol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.
Ulla Olsson-Strömberg, Bengt Simonsson, Tomas Ahlgren, Magnus Björkholm, Karin Carlsson, Claes Malm

Hematol J· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjusted conditioning for allogeneic transplantation in a single center setting: mixed chimerism heralds relapse.
Gunnar Juliusson, Karin Karlsson, Claes Malm, Ulla Frödin, Agneta Seger Mollén

Leuk Lymphoma· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
More potent graft-versus-myeloma effect than graft-versus-renal cell cancer effect.
Gunnar Juliusson, Karin Karlsson, Claes Malm

Leuk Lymphoma· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia.
Helene Hallböök, Bengt Simonsson, Thomas Ahlgren, Magnus Björkholm, Jan Carneskog, Claes Malm

Br J Haematol· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Ulla Axdorph, Leif Stenke, Gunnar Grimfors, Jan Carneskog, Jan Hansen, Claes Malm

Br J Haematol· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis